
Quarterly report 2025-Q3
added 11-06-2025
CONMED Corporation Retained Earnings 2011-2026 | CNMD
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings CONMED Corporation
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 560 M | 453 M | 413 M | 497 M | 457 M | 471 M | 465 M | 440 M | 407 M | 415 M | 406 M | 396 M | 378 M | 354 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 560 M | 354 M | 437 M |
Quarterly Retained Earnings CONMED Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 572 M | 575 M | 560 M | 533 M | 490 M | 466 M | 426 M | 416 M | 408 M | 413 M | 392 M | - | 526 M | 497 M | 478 M | 469 M | 461 M | 457 M | 457 M | 457 M | 457 M | 471 M | 471 M | 471 M | 471 M | 465 M | 465 M | 465 M | 465 M | 440 M | 440 M | 440 M | 440 M | 407 M | 407 M | 407 M | 407 M | 415 M | 415 M | 415 M | 415 M | 406 M | 406 M | 406 M | 406 M | 396 M | 396 M | 396 M | 396 M | 378 M | 378 M | 378 M | 378 M | 354 M | 354 M | 354 M | 354 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 575 M | 354 M | 436 M |
Retained Earnings of other stocks in the Medical devices industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
AxoGen
AXGN
|
-291 M | $ 31.63 | 2.03 % | $ 1.4 B | ||
|
Acutus Medical
AFIB
|
-600 M | - | -26.83 % | $ 2.62 M | ||
|
Boston Scientific Corporation
BSX
|
2.67 B | $ 95.41 | 0.76 % | $ 140 B | ||
|
Abiomed
ABMD
|
828 M | - | - | $ 17.2 B | ||
|
Allied Healthcare Products
AHPI
|
-15.7 M | - | 3.58 % | $ 2.21 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
-533 M | - | - | $ 1.77 B | ||
|
Alphatec Holdings
ATEC
|
-1.28 B | $ 21.25 | 2.36 % | $ 3.04 B | ||
|
Axonics Modulation Technologies
AXNX
|
-374 M | - | - | $ 3.31 B | ||
|
Apyx Medical Corporation
APYX
|
-54.4 M | $ 3.6 | 2.86 % | $ 125 M | ||
|
Cognyte Software Ltd.
CGNT
|
-157 M | $ 9.15 | 2.81 % | $ 657 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
-185 M | - | -5.86 % | $ 30.6 M | ||
|
Bio-Rad Laboratories
BIO
|
7.42 B | $ 320.95 | 5.1 % | $ 9.06 B | ||
|
Apollo Endosurgery
APEN
|
-337 M | - | - | $ 475 M | ||
|
Conformis
CFMS
|
-581 M | - | - | $ 16.4 M | ||
|
BioSig Technologies
BSGM
|
-255 M | - | 37.08 % | $ 85.7 M | ||
|
Bruker Corporation
BRKR
|
2.41 B | $ 50.6 | 5.18 % | $ 7.54 K | ||
|
EDAP TMS S.A.
EDAP
|
-82.6 M | $ 3.48 | 2.35 % | $ 130 M | ||
|
Abbott Laboratories
ABT
|
47.3 B | $ 126.37 | 1.76 % | $ 220 B | ||
|
Cardiovascular Systems
CSII
|
-424 M | - | 0.15 % | $ 844 M | ||
|
Cutera
CUTR
|
-303 M | - | -10.19 % | $ 1.99 M | ||
|
CryoLife, Inc.
CRY
|
20 M | - | -4.14 % | $ 702 M | ||
|
Eargo
EAR
|
-514 M | - | - | $ 10.2 M | ||
|
Electromed
ELMD
|
21.2 M | $ 28.03 | 2.34 % | $ 237 M | ||
|
Soliton, Inc.
SOLY
|
-70.6 M | - | -1.42 % | $ 435 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
-56.2 M | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
-119 M | - | 0.03 % | $ 1.58 B | ||
|
Second Sight Medical Products
EYES
|
-122 M | - | -0.97 % | $ 54.4 M | ||
|
Misonix, Inc.
MSON
|
-39.3 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
-395 M | - | - | $ 111 M | ||
|
Dynatronics Corporation
DYNT
|
-40.5 M | - | 14.99 % | $ 929 K | ||
|
Intersect ENT, Inc.
XENT
|
-303 M | - | - | $ 955 M | ||
|
InMode Ltd.
INMD
|
875 M | $ 15.27 | 3.18 % | $ 1.21 B | ||
|
IRadimed Corporation
IRMD
|
56.8 M | $ 98.11 | 2.73 % | $ 1.24 B | ||
|
Align Technology
ALGN
|
2.48 B | $ 160.18 | 2.66 % | $ 12 B | ||
|
OrthoPediatrics Corp.
KIDS
|
-236 M | $ 18.13 | 3.22 % | $ 418 M | ||
|
Accuray Incorporated
ARAY
|
-519 M | $ 0.89 | 4.38 % | $ 91.5 M | ||
|
Avinger
AVGR
|
-421 M | - | -20.74 % | $ 369 K | ||
|
ClearPoint Neuro
CLPT
|
-191 M | $ 14.34 | 2.21 % | $ 388 M | ||
|
FONAR Corporation
FONR
|
-33.6 M | $ 18.52 | 0.03 % | $ 121 M | ||
|
LivaNova PLC
LIVN
|
-903 M | $ 63.29 | 4.37 % | $ 3.43 B | ||
|
LENSAR
LNSR
|
-143 M | $ 11.32 | -2.5 % | $ 130 M | ||
|
GBS
GBS
|
-62.5 M | - | -0.57 % | $ 7.12 M | ||
|
IRIDEX Corporation
IRIX
|
-79 M | $ 1.21 | 3.42 % | $ 19.5 M | ||
|
Globus Medical
GMED
|
1.15 B | $ 90.81 | 4.02 % | $ 12.3 B | ||
|
Integra LifeSciences Holdings Corporation
IART
|
940 M | $ 12.56 | 4.58 % | $ 967 M | ||
|
Aziyo Biologics
AZYO
|
-176 M | - | 1.37 % | $ 20.5 M | ||
|
Establishment Labs Holdings
ESTA
|
-445 M | $ 65.25 | -5.21 % | $ 1.84 B |